조현병 환자에서의 지연성 운동이상 발생과 세로토닌 1A 수용체유전자 rs6295 다형성과의 연관성

참고문헌 (53)

1. Woods SW, "Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications : a prospective cohort study", J Clin Psychiatry, 71, pp.463~474 (2010)
2. Stegmayer K, "Tardive dyskinesia associated with atypical antipsychotics: prevalence, mechanisms and management strategies", CNS Drugs, 32, pp.135~147 (2018)
3. Casey DE, "Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia", Schizophr Res, 4, pp.109~120 (1991)
4. Frei K, "Tardive dyskinesia : who gets it and why", Parkinsonism Relat Disord, 59, pp.151~154 (2019)
5. Muller DJ, "Familial occurrence of tardive dyskinesia", Acta Psychiatr Scand, 104, pp.375~379 (2001)
6. Weinhold P, "Familial occurrence of tardive dyskinesia", J Clin Psychiatry, 42, pp.165~166 (1981)
7. Baldessarini RJ, "The pathophysiologic basis of tardive dyskinesia", Psychopharmacol Bull, 14, pp.79~81 (1978)
8. Andreassen OA, "Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia?", Prog Neurobiol, 61, pp.525~541 (2000)
9. Haleem DJ, "Enhancement of serotonin-1A receptor dependent responses following withdrawal of haloperidol in rats", Prog Neuropsychopharmacol Biol Psychiatry, 27, pp.645~651 (2003)
10. Naidu PS, "Effect of 5-HT1A and 5-HT2A", 2C receptor modulation on neuroleptic-induced vacuous chewing movements, 2001, pp.428, 81~86
11. Mason SL, "Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue", Eur J Pharmacol, 221, pp.397~398 (1992)
12. Newman-Tancredi A, "Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors", Neuropharmacology, 35, pp.119~121 (1996)
13. Prinssen EP, "Interactions between neuroleptics and 5-HT(1A)ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects", Psychopharmacology(Berl), 144, pp.20~29 (1999)
14. Le Francois B, "Transcriptional regulation at a HTR1A polymorphism associated with mental illness", Neuropharmacology, 55, pp.977~985 (2008)
15. Varnas K, "Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain", Hum Brain Mapp, 22, pp.246~260 (2004)
16. Sumiyoshi T, "Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia", Brain Res, 708, pp.209~214 (1996)
17. Wang L, "The--1019 C", G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients, 2008, pp.22, 904~909
18. Kishi T, "Serotonin 1A receptor gene, schizophrenia and bipolar disorder:an association study and meta-analysis", Psychiatry Res, 185, pp.20~26 (2011)
19. Mossner R, "Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia", Pharmacogenet Genomics, 19, pp.91~94 (2009)
20. Kishi T, "The serotonin 1A receptor gene confer susceptibility to mood disorders : results from an extended meta-analysis of patients with major depression and bipolar disorder", Eur Arch Psychiatry Clin Neurosci, 263, pp.105~118 (2013)
21. Huang YY, "Human 5-HT1A receptor C(-1019)G polymorphism and psychopathology", Int J Neuropsychopharmacol, 7, pp.441~451 (2004)
22. Yen JY, "The effect of serotonin 1A receptor polymorphism on the cognitive function of premenstrual dysphoric disorder", Eur Arch Psychiatry Clin Neurosci, 264, pp.729~739 (2014)
23. Dhingra V, "Serotonin receptor 1A C(-1019)G polymorphism associated with premenstrual dysphoric disorder", Obstet Gynecol, 110, pp.788~792 (2007)
24. Donaldson ZR, "The functional serotonin 1a receptor promoter polymorphism, rs6295, is associated with psychiatric illness and differences in transcription", Transl Psychiatry, 6, pp.e746~ (2016)
25. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders, version IV, text revision (DSM-IV-TR)", American Psychiatric Association, 75~ (2000)
26. Schooler NR, "Research diagnoses for tardive dyskinesia", Arch Gen Psychiatry, 39, pp.486~487 (1982)
27. "Abnormal Involuntary Movement Scale (AIMS)", Psychopharmacol Bull, 24, pp.781~783 (1988)
28. 박영민, "No Evidence for an Association between Dopamine D2 Receptor Polymorphisms and Tardive Dyskinesia in Korean Schizophrenia Patients", PSYCHIATRY INVESTIGATION, 8(1), pp.49~54 (2011), 대한신경정신의학회
29. 이헌정, "No Evidence for Association between Tyrosine Hydroxylase Gene Val81Met Polymorphism and Susceptibility to Tardive Dyskinesia in Schizophrenia", PSYCHIATRY INVESTIGATION, 6(2), pp.108~111 (2009), 대한신경정신의학회
30. Lee HJ, "No association between dopamine D4 receptor gene-521 C", T polymorphism and tardive dyskinesia in schizophrenia, 2007, pp.55, 47~51
31. Lee HJ, "No evidence for an association between G protein beta3 subunit gene C825T polymorphism and tardive dyskinesia in schizophrenia", Hum Psychopharmacol, 22, pp.501~504 (2007)
32. Il-Soo Kim, "No Association between PAWR Gene Polymorphisms and Tardive Dyskinesia in Schizophrenia Patients", PSYCHIATRY INVESTIGATION, 9(2), pp.191~194 (2012), 대한신경정신의학회
33. Kang SG, "Val-158Met polymorphism in the catechol-O-methyltransferase(COMT)gene is not associated with tardive dyskinesia in schizophrenia", Neuropsychobiology, 57, pp.22~25 (2008)
34. Kang SG, "Manganese superoxide dismutase gene Ala-9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.1844~1847 (2008)
35. Kang SG, "No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.1545~1548 (2008)
36. Kang SG, "Association study between glutathione S-transferase GST-M1, GST-T1, and GST-P1polymorphisms and tardive dyskinesia", Hum Psychopharmacol, 24, pp.55~60 (2009)
37. Cho CH, "Oxidative stress and tardive dyskinesia : pharmacogenetic evidence", Prog Neuropsychopharmacol Biol Psychiatry, 46, pp.207~213 (2013)
38. Son WY, "Gaba transporter SLC6A11 gene polymorphism associated with tardive dyskinesia", Nord J Psychiatry, 68, pp.123~128 (2014)
39. Johnson SK, "Neurochemical and motor effects of high dose haloperidol treatment : exacerbation by tryptophan supplementation", Proc Soc Exp Biol Med, 200, pp.571~575 (1992)
40. Haleem DJ, "Differences in the effects of haloperidol and clozapine on brain serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats", Med Sci Monit, 8, pp.BR354~BR361 (2002)
41. Melamed E, "Involvement of serotonin in clinical features of Parkinson’s disease and complications of L-DOPA therapy", Adv Neurol, 69, pp.545~550 (1996)
42. Meltzer HY, "Effects of antipsychotic drugs on serotonin receptors", Pharmacol Rev, 43, pp.587~604 (1991)
43. Segman RH, "Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia", Mol Psychiatry, 6, pp.225~229 (2001)
44. ketanserin binding in human brain postmortem, "Neurochem Res", 1997, 753~757
45. Schmidt CJ, "The role of 5-HT2A receptors in antipsychotic activity", Life Sci, 56, pp.2209~2222 (1995)
46. Rummel-Kluge C, "Second-generation antipsychotic drugs and extrapyramidal side effects : a systematic review and meta-analysis of head-to-head comparisons", Schizophr Bull, 38, pp.167~177 (2012)
47. Gao K, "Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia : a systematic review", J Clin Psychopharmacol, 28, pp.203~209 (2008)
48. Mombereau C, "Involvement of presynaptic 5-HT1A receptors in the low propensity of brexpiprazole to induce extrapyramidal side effects in rats", Pharmacol Biochem Behav, 153, pp.141~146 (2017)
49. Prinssen EP, "5-HT1A receptor activation and anti-cataleptic effects : high-efficacy agonists maximally inhibit haloperidol-induced catalepsy", Eur J Pharmacol, 453, pp.217~221 (2002)
50. Samad N, "Increase in the effectiveness of somatodendritic 5-HT-1A receptors in a rat model of tardive dyskinesia", Acta Neurobiol Exp(Wars), 67, pp.389~397 (2007)
51. Jacobs BL, "Structure and function of the brain serotonin system", Physiol Rev, 72, pp.165~229 (1992)
52. Kelland MD, "Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons", J Pharmacol Exp Ther, 253, pp.803~811 (1990)
53. Haleem DJ, "Somatodendritic and postsynaptic serotonin-1A receptors in the attenuation of haloperidol-induced catalepsy", Prog Neuropsychopharmacol Biol Psychiatry, 28, pp.1323~1329 (2004)

관련 논문AI추천